Full Paper
1
(m, 4H); 13C{1H} NMR (100.6 MHz, CDCl3): d=17.8 (s), 21.9 (s), 30.3
(s), 55.4 (s), 67.8 (s), 68.2 (s), 70.3 (s), 71.1 (s), 84.2 (s), 86.6 (s), 87.2
(s), 89.0 (s), 95.9 (s), 111.1 (s), 113.9 (s), 125.4 (d, 3JCP =10.7 Hz),
127.1 (s), 127.9 (d, 3JCP =9.9 Hz), 130.1 (s, 5), 130.2 (s), 133.8 (s),
134.3 (d, 3JCP =9.4 Hz), 141.4 (s), 158.2 ppm (s); 31P{1H} NMR
(162 MHz, CDCl3): d=23.8 ppm (s); FTIR (KBr): n˜ =3457 (m), 3056
(w), 2961 (w), 2360 (w), 1598 (m), 1526 (m), 1459 (w), 1436 (w),
1386 (w), 1288 (w), 1248 (m), 1179 (w), 1095 (w), 1031 (w), 888 (w),
829 (w), 750 (w), 723 (w), 699 (w), 606 (w), 536 cmꢀ1 (m); HRMS
(ESI): m/z calcd for C45H43ClFeOPRu: 823.11377 [MꢀCl]+; found:
823.11398.
(96%). H NMR (400 MHz, CDCl3): d=0.80–0.94 (m, 144H), 1.70 (br
s, 72H), 2.45 (brs, 24H), 3.25 (brs, 54H), 3.70 (brs, 48H), 4.00 (brs,
48H), 4.09 (brs, 48H), 4.30–4.40 (m, 48H), 5.04 (brs, 96H), 7.02
(brs, 36H), 7.13 (brs, 96H), 7.35 (brs, 144H), 7.63 (brs, 18H),
7.79 ppm (brs, 96H); 13C{1H} NMR (75 MHz, CDCl3): d=17.2 (s), 21.8
(s), 30.0 (s), 67.8 (brs), 72.7 (m), 73.3 (m), 85.3 (s), 85.9 (s), 90.2 (s),
3
95.0 (s), 109.1 (s), 121.4 (brs), 127.2 (brs), 127.6 (d, JCP =10.1 Hz),
130.2 (brs), 132.2–132.5 (m), 134.0 (d, 2JCP =12.1 Hz), 134.6–134.8
(m), 135.5 (s), 136.1 (brs), 136.7 (brs), 148.9 (brs), 151.1–151.3 ppm
(m); 31P{1H} NMR (162 MHz, CDCl3): d=8.4 (s), 18.7 (s), 62.4 (s),
62.6 ppm (s)
1-(4-(4’-Diphenylphosphino)biphenyl)[(p-cymene)dichlororuthe-
nium(II)]-1’-(4-methoxyphenyl)ferrocene (5b-Ru): Compound 5b
(110.0 mg, 0.18 mmol) was treated with di-m-chlorobis[(p-cyme-
ne)chloro-ruthenium(II)] (48.7 mg, 0.08 mmol) according to the
general procedure. Yield: 156.0 mg (95%). Rf (CH2Cl2/ethyl acetate
Complex 8-G3-Ru: Compound 8-G3 (0.0018 mmol) in CH2Cl2 (6 mL)
was treated with di-m-chlorobis[(p-cymene)chlororuthenium(II)]
(26.2 mg, 0.043 mmol) to yield an orange powder. Yield: 74 mg
(96%); 1H NMR (400 MHz, CDCl3): d=0.88 (m, 288H), 1.68 (brs,
144H), 2.43 (brs, 48H), 3.26 (brs), 3.70 (brs, 96H), 3.95–4.15 (m,
192H), 4.33 (brs, 96H), 5.02 (brs, 192H), 7.03 (brs, 84H), 7.14 (brs,
192H), 7.33 (brs, 288H), 7.66 (brs, 126H), 7.78 ppm (brs, 192H);
13C{1H} NMR (100.6 MHz, CDCl3): d=17.2 (s), 21.8 (s), 30.0 (s), 67.7
(m), 72.6 (m), 73.3 (m), 77.9 (m), 85.3 (s), 85.9 (brs), 90.1 (brs), 95.0
1
8:1)=0.60. M.p: 1618C; H NMR (400 MHz, CDCl3): d=1.12 (d, 6H,
3
3JHH =7.0 Hz), 1.90 (s, 3H), 2.88 (sept, 1H, JHH =6.9 Hz), 3.66 (s, 3H),
4.19 (m, 2H), 4.25 (m, 2H), 4.42 (m, 2H), 4.51 (m, 2H), 5.03 (dd, 2H,
3JHH =6.2 Hz, 4JHH =1.4 Hz), 5.23 (d, 2H, 3JHH =6.1 Hz), 6.68 (d, 2H,
3
3
3JHH =8.8 Hz), 7.17 (d, 2H, JHH =8.7 Hz), 7.30 (d, 2H, JHH =8.3 Hz),
7.37–7.44 (m, 8H), 7.60 (dd, 2H, 3JHH =8.5 Hz, 4JHP =2.1 Hz), 7.86–
7.95 ppm (m, 6H); 13C{1H} NMR (75.5 MHz, CDCl3): d=17.8 (s), 21.9
(s), 30.3 (s), 55.2 (s), 67.4 (s), 67.7 (s), 70.0 (s), 70.5 (s), 85.3 (s), 86.9
(s), 87.2 (d, 2JCP =5.2 Hz), 89.1 (d, 2JCP =2.4 Hz), 96.0 (s), 111.2 (d,
3
(brs), 109.1 (s), 121.4 (brs), 127.2 (brs), 127.6 (d, JCP =9.1 Hz), 130.2
(brs), 132.4 (brs), 133.8–134.2 (m), 135.5 (s), 136.1 (brs), 136.7 (brs),
148.8 (d, 2JCP =10.1 Hz), 151.1–151.4 ppm (m); 31P{1H} NMR
(162 MHz, CDCl3): d=8.1 (s), 18.7 (s), 28.4 (s), 62.4 ppm (brs).
Complex 11a-G1-Ru: Compound 11a-G1 (0.0063 mmol) in CH2Cl2
(2 mL) was treated with di-m-chlorobis[(p-cymene)chlororutheniu-
m(II)] (23.5 mg, 0.038 mmol) to yield an orange powder. Yield:
58 mg (79%). 1H NMR (400 MHz, CDCl3): d=1.06 (d, 3JHH =2.8 Hz,
3
2JCP =2.7 Hz), 113.7 (s), 126.0 (d, JCP =10.5 Hz), 126.4 (s), 126.8 (s),
127.0 (s), 128.0 (d, 3JCP =10.1 Hz), 129.6 (s), 130.3 (brs), 131.5 (s),
133.9 (s), 134.3 (d, 2JCP =9.4 Hz), 135.0 (d, 2JCP =9.6 Hz), 137.1 (s),
138.0 (s), 142.5 (s), 158.1 ppm (s); 31P{1H} NMR (162 MHz, CDCl3):
d=23.7 ppm (s); FTIR (KBr): n˜ =3454 (m), 2964 (w), 1631 (m), 1523
(w), 1456 (w), 1261 (w), 1098 (w), 820 (w), 693 (w), 593 (w), 523 (w),
496 (w), 454 (w), 421 cmꢀ1 (w); HRMS (ESI): m/z calcd for
C51H47ClFeOPRu: 899.14525 [MꢀCl]+; found: 899.14444.
3
36H), 1.07 (d, JHH =2.8 Hz, 36H), 1.82 (s, 36H), 2.81 (m, 12H), 3.22
3
(d, JHP =10.2 Hz, 18H), 4.06 (br s, 24H), 4.07 (brs, 24H), 4.29 (brs,
24H), 4.36 (brs, 24H), 4.98 (m, 24H), 5.16 (m, 24H), 6.97–7.07 (m,
36H), 7.15–7.22 (m, 48H), 7.34 (brs, 72H), 7.62–7.70 (m, 42H),
7.83 ppm (m, 48H); 13C{1H} NMR (100.6 MHz, CDCl3): d=17.7 (s),
21.9 (s), 21.9 (s), 30.3 (s), 33.4 (d, 2JCP =10.2 Hz), 68.0 (s), 68.1 (s),
71.0 (s), 71.4 (s), 84.3 (s), 85.0 (s), 86.9 (s), 89.2 (s), 95.7 (s), 110.8 (s),
General procedure for the synthesis of the dendritic rutheni-
um complexes
3
3
121.3 (brs), 125.3 (d, JCP =10.2 Hz), 127.0 (s), 128.0 (d, JCP =9.7 Hz),
128.5 (s), 130.2 (brs), 130.7 (s), 133.9–134.4 (m), 135.6 (brs), 138.4
2
(brs), 141.0 (s), 148.8 (d, JCP =7.1 Hz), 151.2 ppm (brs); 31P{1H} NMR
A solution of the corresponding dendritic ferrocenyl phosphane
dissolved in degassed CH2Cl2 (4 mL) was added to a solution of di-
m-chlorobis[(p-cymene)chloro-ruthenium(II)] in degassed CH2Cl2
(3 mL). The mixture was stirred for 12 h at room temperature, then
concentrated and precipitated into a mixture of hexane/CH2Cl2
(4:1, 40:10 mL). After filtration the orange powder was dried under
vacuo.
(162 MHz, CDCl3): d=8.3 (s), 23.7 (s), 62.6 ppm (s).
Complex 11a-G2-Ru: Compound 11a-G2 (0.0030 mmol) in CH2Cl2
(2 mL) was treated with di-m-chlorobis[(p-cymene)chlororutheniu-
m(II)] (22.0 mg, 0.036 mmol) to yield an orange powder. Yield:
1
53 mg (73%). H NMR (400 MHz, CDCl3): d=1.06 (brs, 144H), 1.80
(brs, 72H), 2.78 (brs, 24H), 3.22 (brs, 54H), 4.13 (brs, 96H), 4.42
(brs, 96H), 4.96 (brs, 48H), 5.13 (brs, 48H), 7.01–7.81 ppm (br m,
534H); 13C{1H} NMR (100.6 MHz, CDCl3): d=17.9 (s), 22.0 (s), 30.3
(s), 33.1 (brs), 68.6 (brs), 71.8 (s), 85.0 (brs), 87.0 (brs), 89.2 (brs),
95.7 (s), 110.8 (s), 121.3 (brs), 121.9 (brs), 125.4 (brs), 127.0 (s),
Complex 8-G1-Ru: Compound 8-G1 (0.0082 mmol) in CH2Cl2 (6 mL)
was treated with (30.0 mg, 0.049 mmol) of di-m-chlorobis[(p-cyme-
ne)chlororuthenium(II)] to yield an orange powder. Yield: 79 mg
(91%); 1H NMR (400 MHz, CDCl3): d=0.90 (d, 72H, 3JHH =7.0 Hz),
3
128.0 (d, JCP =9.6 Hz), 128.7 (s), 130.3 (brs), 130.7 (s), 133.8–134.3
1.72 (s, 36H), 2.48 (sept, 12H), 3.25 (m, 18H), 3.72 (brs, 24H), 4.00
3
(m), 135.5 (brs), 138.4 (brs), 148.8 (brs), 150.0 (s), 151.2 ppm (brs);
31P{1H} NMR (162 MHz, CDCl3): d=8.3 (s), 24.0 (s), 62.5 (s), 62.8 ppm
(s).
(brs, 24H), 4.08 (brs, 24H), 4.37 (brs, 24H), 5.06 (dd, 48H, JHP
=
=
3
3
3
15.2, JHH =5.5 Hz), 6.93 (d, 12H, JHH =6.6 Hz), 7.01 (d, 24H, JHH
8.1 Hz), 7.12 (d, 3JHH =8.1 Hz, 24H), 7.31–7.44 (m, 72H), 7.55–7.70
(m, 18H), 7.81 ppm (dd, 48H, JHP =8.6, JHH =8.6 Hz); 13C{1H} NMR
3
3
Complex 11a-G3-Ru: Compound 11a-G3 (0.0021 mmol) in CH2Cl2
(2 mL) was treated with di-m-chlorobis[(p-cymene)chlororutheniu-
m(II)] (31.0 mg, 0.051 mmol) to yield an orange powder. Yield:
85 mg (82%). 1H NMR (400 MHz, CDCl3): d=1.00 (m, 288H), 1.76
(brs, 144H), 2.75 (brs, 48H), 3.19 (brs, 126H), 4.05 (brs, 192H), 4.29
(m, 192H), 4.93 (brs, 96H), 5.10 (brs, 96H), 7.00 (brs, 84H), 7.15
(brs, 288H), 7.28 (brs, 288H), 7.62 (brs, 222H), 7.78 ppm (brs,
192H); 13C{1H} NMR (100.6 MHz, CDCl3): d=17.8 (s), 21.9 (m), 30.2
(brs), 68.0–68.3 (m), 70.8–71.5 (m), 84.2 (brs), 85.0–85.2 (m), 86.9–
87.1 (m), 89.1–89.4 (m), 95.5 (s), 110.6 (s), 121.3 (brs), 125.2–125.4
(m), 127.0 (brs), 128.0 (d, 3JCP =11.1 Hz), 130.2 (brs), 130.8 (brs),
(75 MHz, CDCl3): d=17.2 (s), 21.8 (s), 26.9 (s), 30.0 (s), 67.7 (s), 72.6
2
2
(s), 73.2 (m), 76.0 (m), 85.3 (s), 85.9 (d, JCP =5.4 Hz), 90.2 (d, JCP
=
4
3.1 Hz), 95.0 (s), 109.2 (s), 121.2 (d, JCP =3.3 Hz), 121.4 (brs), 127.2
(s), 128.2 (d, 3JCP =9.6 Hz), 128.5 (s), 130.2 (s), 130.8 (s), 134.0 (d,
2JCP =9.3 Hz), 135.5 (s), 136.2 (s), 136.8 (brs), 148.8 (d, JCP =7.2 Hz),
2
151.2 ppm (d, 2JCP =4.3 Hz); 31P{1H} NMR (162 MHz, CDCl3): d=8.6
(s), 18.7 (s), 62.4 ppm (s).
Complex 8-G2-Ru: Compound 8-G2 (0.0040 mmol) in CH2Cl2 (7 mL)
was treated with di-m-chlorobis[(p-cymene)chlororuthenium(II)]
(30.0 mg, 0.049 mmol) to yield an orange powder. Yield: 86 mg
Chem. Eur. J. 2015, 21, 1 – 16
13
ꢀ 2015 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
&
&
These are not the final page numbers! ÞÞ